Semax

A synthetic heptapeptide derived from the ACTH(4-10) fragment with a Pro-Gly-Pro (PGP) tripeptide extension at the C-terminus that confers enzymatic stability. Originally developed in Russia and approved there as a prescription nootropic and neuroprotective agent, Semax enhances BDNF expression and modulates monoamine neurotransmitter systems.

• Increases BDNF and trkB receptor expression in the hippocampus and cortex
• Modulates dopaminergic, serotonergic, and noradrenergic neurotransmission
• Inhibits enkephalinase activity, prolonging endogenous enkephalin signaling
• Melanocortin receptor (MC3/MC4) activation contributes to neuroprotective and anti-inflammatory effects

• Active seizure disorders (may lower seizure threshold in susceptible individuals)
• Pregnancy or breastfeeding
• Known hypersensitivity to ACTH-derived peptides

Store at 2–8°C (36–46°F) for up to 6 months, protected from light. Nasal spray solutions: refrigerate and use within 30 days of opening.

Often supplied as a pre-made nasal spray solution (0.1% or 1%). If lyophilized, reconstitute with bacteriostatic water for subcutaneous use.

Semax has been approved in Russia and several CIS countries since 1994 for conditions including stroke recovery, cognitive impairment, and optic nerve atrophy. Russian clinical trials demonstrated improved cognitive scores in post-stroke patients and enhanced memory in healthy volunteers. Research shows robust BDNF upregulation (2-4 fold increases in hippocampal tissue) and significant neuroprotection in ischemia models. It is one of the most well-studied nootropic peptides globally, though it lacks Western regulatory trials.